IgA肾病蛋白尿缓解持续时间与临床结局的量化关联
该回顾性多民族队列纳入1864例成人IgA肾病患者,定义蛋白尿缓解为峰值下降≥25%且绝对值<1 g/d,采用时依Cox模型分析首次缓解持续时间与主要结局(ESKD或eGFR下降50%)的关联。中位随访3.9年,274例(14.7%)发生主要结局;缓解持续至约4年内每3个月与进展风险额外降低9%相关(HR 0.91,95%CI 0.89–0.93),此后额外3个月风险降低不显著(HR 0.99,95%CI 0.96–1.03)。
要点
- 蛋白尿缓解持续时间与IgA肾病进展风险呈非线性关系。
- 持续缓解约4年内,每3个月与进展风险降低9%相关。
- 超过约4年后,额外缓解时间的风险降低不显著。
核心结论
- 蛋白尿可作为IgA肾病的替代结局,量化缓解持续时间有助于估计硬临床终点风险。
研究设计与样本
- 回顾性多民族成人IgA肾病队列,共1864例,中位随访3.9年。
- 蛋白尿缓解定义为峰值下降≥25%且绝对值<1 g/d,首次缓解持续时间作为时依协变量。
- 采用时依Cox比例风险模型分析缓解持续时间与主要结局的关联。
主要发现
- 274/1864例(14.7%)发生主要结局(ESKD或eGFR下降50%)。
- 缓解持续时间与结局关系非线性;持续缓解至约4年内每3个月HR 0.91(95%CI 0.89–0.93)。
- 约4年后每额外3个月HR 0.99(95%CI 0.96–1.03),风险降低不显著。
- 结果经多变量调整稳健,且在临床与组织学亚组中一致。
关键数值与推荐
- 蛋白尿缓解标准:较活检后峰值下降≥25%且绝对值<1 g/d。
- 主要结局:ESKD或eGFR下降50%。
- 持续缓解约4年内每3个月HR 0.91(95%CI 0.89–0.93);此后每3个月HR 0.99(95%CI 0.96–1.03)。
临床怎么用
- 在IgA肾病管理中应关注蛋白尿缓解的维持时间,而不仅是单次降幅。
- 持续缓解约4年内每延长3个月均与进展风险进一步降低相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: On the basis of findings of observational studies and a meta-analysis, proteinuria reduction has been proposed as a surrogate outcome in IgA nephropathy. How long a reduction in proteinuria needs to be maintained to mitigate the long-term risk of disease progression is unknown. METHODS: In this retrospective multiethnic cohort of adult patients with IgA nephropathy, we defined proteinuria remission as a ≥25% reduction in proteinuria from the peak value after biopsy, and an absolute reduction in proteinuria to <1 g/d. The exposure of interest was the total duration of first remission, treated as a time-varying covariate using longitudinal proteinuria measurements. We used time-dependent Cox proportional hazards regression models to quantify the association between the duration of remission and the primary outcome (ESKD or a 50% reduction in eGFR). RESULTS: During a median follow-up of 3.9 years, 274 of 1864 patients (14.7%) experienced the primary outcome. The relationship between duration of proteinuria remission and outcome was nonlinear. Each 3 months in sustained remission up to approximately 4 years was associated with an additional 9% reduction in the risk of disease progression (hazard ratio [HR], 0.91; 95% confidence interval [95% CI], 0.89 to 0.93). Thereafter, each additional 3 months in remission was associated with a smaller, nonsignificant risk reduction (HR, 0.99; 95% CI, 0.96 to 1.03). These findings were robust to multivariable adjustment and consistent across clinical and histologic subgroups. CONCLUSIONS: Our findings support the use of proteinuria as a surrogate outcome in IgA nephropathy, but additionally demonstrate the value of quantifying the duration of proteinuria remission when estimating the risk of hard clinical endpoints.
引用
- Canney M, Barbour SJ, Zheng Y, et al. Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. J Am Soc Nephrol. 2020. PMID: 33514642. doi:10.1681/ASN.2020030349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。